β-blocker use for the stages of heart failure

Mayo Clinic Proceedings

Volumn 84, Issue 8, 2009, Pages 718-729

  Klapholz, Marc ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LABETALOL; NADOLOL; PINDOLOL; PROPRANOLOL DERIVATIVE;

ALCOHOL CONSUMPTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; OBESITY; REVIEW; TREATMENT OUTCOME;

EID: 68149159125     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.8.718     Document Type: Review

References (92)

1. Cohn JN, Ferrari R, Sharpe N; International Forum on Cardiac Remodeling. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569-582.
2. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial]. J Am Coll Cardiol. 1992;20(1):248-254.
3. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819-823.
4. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A; V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation. 1993;87(6)(suppl):V140-V148.
5. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26(5):1257-1263.
6. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
8. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation. 2005 Sep 20;112(12):e154-e235. Epub 2005 Sep 13.
9. Packer M, Bristow MR, Cohn JN, et al; US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med. 1996;334(21):1349-1355.
10. Francis GS, Benedict C, Johnstone DE, et al; SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82(5):1724-1729.
11. Criteria Committee of the New York Heart Association, Dolgin M, Fox AC, Gorlin R, Levin RI, eds. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little, Brown & Co; 1994.
12. Ventura HO. Benefits of inpatient initiation of β-blockers. Am Heart J. 2004;148(6):944-950.
13. Bhatia GS, Sosin MD, Grindulis KA, Davis RC, Lip GY. Rheumatoid disease and the heart: from epidemiology to echocardiography. Expert Opin Investig Drugs. 2005;14(1):65-76.
14. Pedersen ME, Cockcroft JR. The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep. 2006;8(4):279-286.
15. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269-277.
16. Bangalore S, Messerli FH. β-Blockers as fourth-line therapy for hypertension: stay the course. Int J Clin Pract. 2008;62(11):1643-1646.
17. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117(20):2706-2715.
18. Weber MA, Bakris GL, Giles TD, Messerli FH. Beta-blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens (Greenwich). 2008;10(3):234-238.
19. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562.
20. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med. 1996;156(16):1789-1796.
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ. 1999;318(7175):29]. BMJ. 1998;317(7160):703-713.
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289(2):178 and 2004;291(18):2196]. JAMA. 2002;288(23):2981-2997.
23. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277(9):739-745.
24. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007 Aug 14;50(7):563-572. Epub 2007 Jul 30.
25. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst. 2006;7(2):61-63.
26. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-1252. Epub 2003 Dec 1.
27. Dahlof B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
28. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52(18):1482-1489.
29. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. J Am Coll Cardiol. 2008;52(13):1062-1072.
30. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17(2):118-123.
31. Williams B, Lacy PS, Thom SM, et al; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006 Mar 7;113(9):1213-1225. Epub 2006 Feb 13.
32. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816.
33. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest. 2005;127(3):818-824.
34. Abraham WT. Switching between beta blockers in heart failure patients: rationale and practical considerations. Congest Heart Fail. 2003;9(5):271-278.
35. Bell DS. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care. 1995;18(5):708-714.
36. Wilson CS, Gau GT, Fulton RE, Davis GD. Coronary artery disease in diabetic and nondiabetic patients: a clinical and angiographic comparison. Clin Cardiol. 1983;6(9):440-446.
37. Bell DS. Hypertension in the person with diabetes. Am J Med Sci. 1989;297(4):228-232.
38. Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol. 2001;37(7):1943-1949.
39. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241(19):2035-2038.
40. Bourassa MG, Gurné O, Bangdiwala SI, et al; The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(4)(suppl A):14A-19A.
41. Chae CU, Glynn RJ, Manson JE, Guralnik JM, Taylor JO, Pfeffer MA. Diabetes predicts congestive heart failure risk in the elderly. Circulation. 1998;98(suppl I):721.
42. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103(22):2668-2673.
43. Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004;93(7):870-875.
44. Vinereanu D, Nicolaides E, Tweddel AC, et al. Subclinical left ventricular dysfunction in asymptomatic patients with type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci (Lond). 2003;105(5):591-599.
45. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006 Oct 12;355(15):1551-1562. Epub 2006 Sep 15.
46. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338(10):645-652.
47. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342(18):1376 and 2000;342(10):748]. N Engl J Med. 2000;342(3):145-153.
48. Bell DS. Beta-adrenergic blocking agents in patients with diabetes: friend and foe. Endocr Pract. 1999;5(1):51-53.
49. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL; Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342(13):905-912.
50. Lindholm LH, Ibsen H, Borch-Johnsen K, et al; LIFE Study Group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20(9):1879-1886.
51. Olsen MH, Fossum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens. 2005;23(4):891-898.
52. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2236.
53. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med. 1997;126(12):955-959.
54. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study [published correction appears in J Hypertens. 1996;14(11):1382]. J Hypertens. 1996;14(4):489-494.
55. Falkner B, Francos G, Kushner H. Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertens (Greenwich). 2006;8(5):336-343.
56. 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 1994;43(4):455-461.
57. Pfeffer MA, Braunwald E, Moyé LA, et al; SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327(10):669-677.
58. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published correction appears in N Engl J Med. 1992;327(24):1768]. N Engl J Med. 1992;327(10):685-691.
59. Tsikouris JP, Cox CD. Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy. 2003;23(9):1141-1152.
60. Grimm RH Jr. Antihypertensive therapy: taking lipids into consideration. Am Heart J. 1991;122(3, pt 2):910-918.
61. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122(2):133-141.
62. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003 Aug 26;108(8):977-982. Epub 2003 Aug 11.
63. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol. 1999;33(4):916-923.
64. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97(3):282-289.
65. Vantrimpont P, Rouleau JL, Wun CC, et al; SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol. 1997;29(2):229-236.
66. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-1390.
67. Philippides GJ. Managing the post-myocardial infarction patient with asymptomatic left ventricular dysfunction. Cardiology. 2006;105(2):95-107. Epub 2005 Dec 7.
68. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation. 2006;113(24):2851- 2860.
69. McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45(4):525-530.
70. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N; CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004 Jan 20;109(2):201-206. Epub 2004 Jan 5.
71. Remme WJ, Riegger G, Hildebrandt P, et al; CARMEN Investigators and Co-ordinators. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction: the carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004;18(1):57-66.
72. Colucci WS, Kolias TJ, Adams KF, et al; REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation. 2007 Jul 3;116(1):49-56. Epub 2007 Jun 18.
73. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349(9049):375-380.
74. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-1658.
75. Packer M, Fowler MB, Roecker EB, et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002;106(17):2194-2199.
76. Poole-Wilson PA, Swedberg K, Cleland JG, et al; COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.
77. Bristow MR, Gilbert EM, Abraham WT, et al; MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94(11):2807-2816.
78. Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother. 2006;7(18):2533- 2546.
79. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659-1667.
80. Fowler MB, Vera-Llonch M, Oster G, et al; U.S. Carvedilol Heart Failure Study Group. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. J Am Coll Cardiol. 2001;37(6):1692-1699.
81. Colucci WS, Packer M, Bristow MR, et al; US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94(11):2800-2806.
82. Hjalmarson A, Goldstein S, Fagerberg B, et al; MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). JAMA. 2000;283(10):1295-1302.
83. 125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003;460(1):19-26.
84. de Groote P, Delour P, Lamblin N, et al. Effects of bisoprolol in patients with stable congestive heart failure. Ann Cardiol Angeiol (Paris). 2004;53(4):167-170.
85. Eichhorn EJ, Grayburn PA, Mayer SA, et al; BEST Investigators. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with β-blockade in patients with heart failure: the β-Blocker Evaluation of Survival Trial (BEST). Circulation. 2003 Nov 11;108(19):2336-2341. Epub 2003 Nov 3.
86. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11288-11293. Epub 2006 Jul 14.
87. Remme WJ, Torp-Pedersen C, Cleland JG, et al. Carvedilol pro tects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol. 2007 Mar 6;49(9):963-971. Epub 2007 Feb 20.
88. Torp-Pedersen C, Metra M, Charlesworth A, et al; COMET Investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007 Aug;93(8):968-973. Epub 2007 Jan 19.
89. Metra M, Torp-Pedersen C, Swedberg K, et al; COMET Investigators. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005 Nov;26(21):2259-2268. Epub 2005 Jul 21.
90. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141(6):899-907.
91. Katus HA, Tendera M, Mohacsi P, et al; COPERNICUS Study Group. Effect of carvedilol on major clinical events in patients with severe heart failure and an extremely depressed ejection fraction: results of the COPERNICUS study [abstract 810-2]. J Am Coll Cardiol. 2002;39(suppl 1):155A
92. Rose EA, Gelijns AC, Moskowitz AJ, et al; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.